Alexa Fluor® 568 Anti-Cytochrome P450 1A2 抗体 [EPR6138(2)]
Alexa Fluor® 568 Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]
- RabMAb
- Recombinant
- 詳細を見る
Be the first to review this product! Submit a review
|
(0 Publication)
Rabbit Recombinant Monoclonal Cytochrome P450 1A2 antibody - conjugated to Alexa Fluor® 568.
別名を表示する
Cytochrome P450 1A2, CYPIA2, Cholesterol 25-hydroxylase, Cytochrome P(3)450, Cytochrome P450 4, Cytochrome P450-P3, Hydroperoxy icosatetraenoate dehydratase, CYP1A2
関連する標識済み抗体及び組成の異なる製品 (6)
-
578 PE
PE Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]
-
660 APC
APC Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]
-
617 Alexa Fluor® 594
Alexa Fluor® 594 Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]
-
565 Alexa Fluor® 555
Alexa Fluor® 555 Anti-Cytochrome P450 1A2 antibody [EPR6138(2)]
製品の詳細
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
出荷温度及び保存条件
製品の状態
精製方法
バッファー組成
出荷温度
短期保存期間
短期保存温度
長期保存温度
分注に関する情報
保管に関する情報
補足情報
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
CYP1A2 plays a central role in the oxidative biotransformation of drugs and procarcinogens. It does not form part of a larger complex but interacts dynamically with other enzymes in the detoxification process. CYP1A2 metabolizes several clinical drugs such as caffeine and theophylline and regulates the detoxification of aromatic amines and hydrocarbons. Studying CYP1A2 inhibitors can provide insights into clinically relevant drug interactions and potential side effects in pharmacotherapy.
Pathways
CYP1A2 functions within the drug metabolism and synthesis of cholesterol steroids and other lipids pathways. In the drug metabolism pathway CYP1A2 works alongside other cytochrome P450 enzymes such as CYP1A1 and CYP1B1 which together ensure the metabolism and clearance of various exogenous and endogenous compounds. These pathways are vital for maintaining drug efficacy and preventing toxicity through the metabolic clearance of pharmaceutical agents and harmful substances.
製品プロトコール
- Visit the General protocols
- Visit the Troubleshooting
ターゲットの情報
Abcam product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com